ITCI Nov 2024 80.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 01:30PM EDT
| Previous close | 4.2000 |
| Open | 3.1000 |
| Bid | 0.7000 |
| Ask | 5.4000 |
| Strike | 80.00 |
| Expiry date | 2024-11-15 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Investor's Business DailyIntra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
© 2024 Yahoo. All rights reserved.